These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 6323206)

  • 21. Cannabichromene and delta 9-tetrahydrocannabinol: interactions relative to lethality, hypothermia and hexobarbital hypnosis.
    Hatoum NS; Davis WM; Elsohly MA; Turner CE
    Gen Pharmacol; 1981; 12(5):357-62. PubMed ID: 6269951
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis and pharmacological evaluation of amino, azido, and nitrogen mustard analogues of 10-substituted cannabidiol and 11- or 12-substituted delta 8-tetrahydrocannabinol.
    Compton DR; Little PJ; Martin BR; Gilman JW; Saha JK; Jorapur VS; Sard HP; Razdan RK
    J Med Chem; 1990 May; 33(5):1437-43. PubMed ID: 2158563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: effect on intraocular pressure in rabbits.
    Muchtar S; Almog S; Torracca MT; Saettone MF; Benita S
    Ophthalmic Res; 1992; 24(3):142-9. PubMed ID: 1328979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ocular hypotensive effects of an intratracheally delivered liposomal delta9-tetrahydrocannabinol preparation in rats.
    Szczesniak AM; Kelly ME; Whynot S; Shek PN; Hung O
    J Ocul Pharmacol Ther; 2006 Jun; 22(3):160-7. PubMed ID: 16808676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Central excitatory properties of delta 9-tetrahydrocannabinol and its metabolites in iron-induced epileptic rats.
    Turkanis SA; Karler R
    Neuropharmacology; 1982 Jan; 21(1):7-13. PubMed ID: 6278353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part II: comparison of behavioural effects of pulmonary versus parenteral cannabinoid exposure in rodents.
    Manwell LA; Ford B; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):112-9. PubMed ID: 24956154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
    Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
    J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors affecting the response of the female rat reproductive system to cannabinoids.
    O'Connell ME; Morrill GA; Fujimoto GI; Kostellow AB
    Toxicol Appl Pharmacol; 1987 May; 88(3):411-7. PubMed ID: 3033848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.
    González S; Fernández-Ruiz J; Di Marzo V; Hernández M; Arévalo C; Nicanor C; Cascio MG; Ambrosio E; Ramos JA
    Drug Alcohol Depend; 2004 May; 74(2):159-70. PubMed ID: 15099659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Quantitative analysis and pharmaco-toxicity of cannabinoids in commercially available cannabis seeds].
    Matsunaga T; Watanabe K; Yoshimura H; Yamamoto I
    Yakugaku Zasshi; 1998 Sep; 118(9):408-14. PubMed ID: 9779001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats.
    Nakamura-Palacios EM; Amodeo Bueno OF; Takahashi RN; Tufik S
    Pharmacol Biochem Behav; 2002 Dec; 74(1):205-12. PubMed ID: 12376169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of agonist-antagonist properties of nitrogen mustard and cyano derivatives of delta 8-tetrahydrocannabinol.
    Wiley JL; Compton DR; Gordon PM; Siegel C; Singer M; Dutta A; Lichtman AH; Balster RL; Razdan RK; Martin BR
    Neuropharmacology; 1996; 35(12):1793-804. PubMed ID: 9076759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol.
    Romero J; García L; Fernández-Ruiz JJ; Cebeira M; Ramos JA
    Pharmacol Biochem Behav; 1995 Aug; 51(4):731-7. PubMed ID: 7675852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma.
    Merritt JC; Perry DD; Russell DN; Jones BF
    J Clin Pharmacol; 1981; 21(S1):467S-471S. PubMed ID: 6271841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
    Janoyan JJ; Crim JL; Darmani NA
    Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.
    Laine K; Järvinen K; Mechoulam R; Breuer A; Järvinen T
    Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3216-22. PubMed ID: 12356827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration.
    Anikwue R; Huffman JW; Martin ZL; Welch SP
    J Pharmacol Exp Ther; 2002 Oct; 303(1):340-6. PubMed ID: 12235269
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological potency of R- and S-3'-hydroxy-delta 9-tetrahydrocannabinol: additional structural requirement for cannabinoid activity.
    Martin BR; Kallman MJ; Kaempf GF; Harris LS; Dewey WL; Razdan RK
    Pharmacol Biochem Behav; 1984 Jul; 21(1):61-5. PubMed ID: 6087379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA; Johnson JC
    Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs.
    Fischer KM; Ward DA; Hendrix DV
    Am J Vet Res; 2013 Feb; 74(2):275-80. PubMed ID: 23363354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.